Tag: John-Donoghue

2 articles

Industry News

Precision Neuroscience appoints John Donoghue as scientific advisor

On Thursday 23 July 2026, New York-based Precision Neuroscience announced the appointment of John Donoghue - founding investigator of the BrainGate consortium at Brown, co-founder of Cyberkinetics, and inaugural director of the Wyss Center for Bio and Neuroengineering in Geneva - as a scientific advisor to the company. Donoghue will advise Precision's scientific and engineering teams on device design, signal decoding, and clinical strategy. The appointment lands two days after Precision's non-paralysed cursor-control demonstration across its 15-plus academic-medical-centre clinical network, and at exactly the moment ABILITY Neurotech, the Wyss Center spin-out whose technology was conceived under Donoghue's own directorship, prepares to begin its own chronic first-in-human implantation in ALS patients.

Jul 25

Industry News

ABILITY Neurotech reaches first-in-human at TUM Munich

On Tuesday 21 July 2026, Geneva-based ABILITY Neurotech announced the first-in-human recording of its fully implantable, batteryless brain-computer interface at TUM University Hospital Rechts der Isar in Munich. The device is a 128-channel sub-scalp ECoG array with a laser-based transcutaneous optical data link streaming raw neural signals through the scalp at 50 megabits per second. The first cohort is up to five brain-tumour surgery patients recording 20 to 30 minutes of intraoperative data each. The company's separate chronic implantation trial in ALS patients at UMC Utrecht, cleared by Dutch regulators on 26 May 2026, has not yet performed a surgery.

Jul 24